Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Zhang, Jian ^a   Huang, Shao Hong ^a   Li, Hui ^a   Li, Yun ^a   Chen, Xiu Ling ^a   Zhang, Wei Qing ^a   Chen, Hui Guo ^a   Gu, Li Jia ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Disease free survival; Lymphatic count; Lymphatic invasion; Neutrophil count; Non small cell lung cancer; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPH VESSEL METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; NEUTROPHIL COUNT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR INVASION;

ADOLESCENT; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84871588769     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0352-3     Document Type: Article

References (35)

1. Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111(6):1710-7.
3. O'Dowd C, et al. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol. 2010;5(7):988-92.
4. Tauler J, Mulshine JL. Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol. 2009;9(4):384-8.
5. Kobayashi N, et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer. 2012;75(2):223-7.
6. Fietta AM, et al. Systemic inflammatory response and downmodulation of peripheral CD25+ Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol. 2009;70(7):477-86.
7. Wislez M, et al. Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. Clin Cancer Res. 2007;13(12):3518-27.
8. Hespanhol V, et al. Survival predictors in advanced non-small cell lung cancer. Lung Cancer. 1995;13(3):253-67.
9. Muers MF, Shevlin P, Brown J. Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model. Thorax. 1996;51(9):894-902.
10. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260-71.
11. Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(7):593-602.
12. Fogar P, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32(1):22-8.
13. Clark EJ, et al. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2007;9(6):456-60.
14. Ownby HE, et al. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer. 1983;52(1):126-30.
15. Espinosa E, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 1995;12(1-2):67-76.
16. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45.
17. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
18. Gooden MJ, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93-103.
19. Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-13.
20. Mlecnik B, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610-8.
21. Kawai O, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113(6):1387-95.
22. Hiraoka K, et al. Concurrent infiltration by CD8(+) T cells and CD4(+) T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94(2):275-80.
23. Zikos TA, et al. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother. 2011;60(6):819-27.
24. Donnem T, et al. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010;116(18):4318-25.
25. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411(6835):380-4.
26. Wakabayashi O, et al. CD4(+) T cells in cancer stroma, not CD8(+) T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94(11):1003-9.
27. Mori M, et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med. 2000;191(2):113-8.
28. Kim HJ, et al. Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes. PLoS ONE. 2011;6(10):e26264.
29. Kopfstein L, et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol. 2007;170(4):1348-61.
30. Al-Shibli KI, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16):5220-7.
31. Park SY, et al. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thorac Surg. 2011;91(6):1668-73.
32. Igai H, et al. Clinicopathological study of p-T1aN0M0 non-small-cell lung cancer, as defined in the seventh edition of the TNM classification of malignant tumors. Eur J Cardiothorac Surg. 2011;39(6):963-7.
33. Biaoxue R, et al. Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers. 2011;26(1):9-21.
34. Sarraf KM, et al. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425-8.
35. Teramukai S, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45(11):1950-8.